

Frederick J Raal

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6783950/frederick-j-raal-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

199
papers

16,634
citations

50
h-index

128
g-index

224
ext. papers

20,697
ext. citations

8.1
avg, IF

6.41
L-index

#	Paper	IF	Citations
199	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. <i>Lancet, The</i> , 2022 ,	4.0	4
198	Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia.. <i>Journal of Clinical Lipidology</i> , 2022 ,	4.9	
197	Agranulocytosis as a Side-Effect of Carbimazole. <i>Wits Journal of Clinical Medicine</i> , 2022 , 4, 61-63	0.5	
196	Statins: are they appropriate for all patients?. <i>The Lancet Global Health</i> , 2022 , 10, e305-e306	13.6	
195	Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge. <i>Cardiology and Therapy</i> , 2021 , 11, 1	2.8	0
194	Acute Suppurative Thyroiditis Secondary to Infection.. <i>European Journal of Case Reports in Internal Medicine</i> , 2021 , 8, 003009	1.2	0
193	Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. <i>Future Cardiology</i> , 2021 ,	1.3	2
192	Management of familial hypercholesterolemia in pregnancy. <i>Current Opinion in Lipidology</i> , 2021 , 32, 370-377	4.4	2
191	Novel therapies for familial hypercholesterolemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021 , 28, 188-195	4	1
190	Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 379-380	4.9	2
189	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1182-1193	15.1	31
188	Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. <i>Atherosclerosis</i> , 2021 , 320, 53-60	3.1	12
187	Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 657719	5.4	1
186	Inhibition of angiotensin-like 3 for the management of severe hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2021 , 32, 213-218	4.4	10
185	Hyperpigmentation from Addison's Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 1752	59.2	
184	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021 , 325, 46-56	3.1	5
183	Poor cardiovascular health is associated with subclinical atherosclerosis in apparently healthy sub-Saharan African populations: an H3Africa AWI-Gen study. <i>BMC Medicine</i> , 2021 , 19, 30	11.4	1

182	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021 , 398, 1713-1725	40	14
181	Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction. <i>American Journal of Preventive Cardiology</i> , 2021 , 7, 100224	1.9	4
180	Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female. <i>Clinica Chimica Acta</i> , 2021 , 520, 71-75	6.2	1
179	Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. <i>Atherosclerosis Plus</i> , 2021 , 43, 3-6		2
178	Never too old to benefit from lipid-lowering treatment. <i>Lancet, The</i> , 2020 , 396, 1608-1609	40	4
177	Cryptogenic Cushing Syndrome Due to a White Lie. <i>Clinical Chemistry</i> , 2020 , 66, 658-663	5.5	0
176	An unusual presentation of insulinoma and the serious consequences of delayed diagnosis. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2020 , 25, 28-30	0.5	1
175	Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. <i>Circulation</i> , 2020 , 141, 1829-1831	16.7	29
174	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , 2020 , 382, 1507-1519	59.2	302
173	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020 , 382, 1520-1530	59.2	197
172	Homozygous familial hypercholesterolemia and its treatment by inclisiran. <i>Expert Opinion on Orphan Drugs</i> , 2020 , 8, 197-208	1.1	0
171	Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations. <i>PLoS ONE</i> , 2020 , 15, e0229098	3.7	3
170	Pattern of dyslipidaemia in relation to statin use in patients with type 2 diabetes mellitus attending a tertiary care hospital. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2020 , 25, 6-11	0.5	1
169	Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 565-574	15.1	65
168	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <i>Nature Reviews Cardiology</i> , 2020 , 17, 360-377	14.8	41
167	An unusual case of hypercholesterolaemia with liver dysfunction. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2020 , 25, 31-35	0.5	
166	Demographic and Clinical Factors Associated with Development of Type 2 Diabetes: A Review of the Literature. <i>International Journal of General Medicine</i> , 2020 , 13, 121-129	2.3	16
165	LIPID AND LIPOPROTEIN LEVELS IN HIV-INFECTED ADULTS WITH SEPSIS COMPARED TO HEALTHY HIV- INFECTED CONTROLS. <i>African Journal of Infectious Diseases</i> , 2020 , 14, 1-9	0.5	1

164	PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020 , 20, 840-854	2.2	3
163	Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11). <i>European Heart Journal</i> , 2020 , 41,	9.5	2
162	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020 , 41, 2313-2330	9.5	301
161	Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 2747-2755	9.4	1
160	Evinacumab for Homozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020 , 383, 711-720	59.2	166
159	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 50-67	18.1	48
158	LONG-TERM EVOLOCUMAB USE IN SUBJECTS WITH HOMOZYGOUS AND SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: PRIMARY RESULTS OF THE TAUSSIG TRIAL. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1715	15.1	2
157	Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 61	2.3	2
156	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 69-76	3.9	9
155	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 735-743	4.9	1
154	More aggressive lipid lowering in people with diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 587-589	18.1	1
153	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2132-2146	15.1	58
152	Management of low-density lipoprotein cholesterol levels in South Africa: the International Cholesterol management Practice Study (ICLPS). <i>Cardiovascular Journal of Africa</i> , 2019 , 30, 15-23	0.7	5
151	Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. <i>Cardiovascular Journal of Africa</i> , 2019 , 30, 279-284	0.7	1
150	A pain in the neck. <i>BMJ, The</i> , 2019 , 367, l6008	5.9	
149	Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. <i>Current Atherosclerosis Reports</i> , 2019 , 21, 48	6	19
148	Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. <i>Aids</i> , 2019 , 33, 2049-2059	3.5	4
147	Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa. <i>Current Opinion in Lipidology</i> , 2018 , 29, 72-79	4.4	10

146	Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 592-598	9.4	49
145	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018 , 39, 2526-2539	9.5	156
144	Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. <i>Archives of Public Health</i> , 2018 , 76, 15	2.6	13
143	Fibroblast growth factor-23 in patients with homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 767-772	4.9	0
142	Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. <i>European Heart Journal</i> , 2018 , 39, 1162-1168	9.5	54
141	Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , 2018 , 41, 1328-1335	3.3	21
140	Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 1199-1207	4.9	15
139	DETECTION OF FAMILIAL HYPERCHOLESTEROLEMIA IN SOUTH AFRICA VIA CASCADE SCREENING: THE WITS FIND-FH PROGRAM. <i>Journal of the American College of Cardiology</i> , 2018 , 71, A1768	15.1	2
138	Familial hypercholesterolemia treatments: Guidelines and new therapies. <i>Atherosclerosis</i> , 2018 , 277, 483-492	3.1	72
137	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018 , 277, 234-255	3.1	93
136	Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. <i>Atherosclerosis</i> , 2018 , 277, 502-507	3.1	21
135	Quality of care delivered to type 2 diabetes mellitus patients in public and private sector facilities in Johannesburg, South Africa. <i>International Journal of General Medicine</i> , 2018 , 11, 383-390	2.3	3
134	Clinical, demographic and genetic characteristics of homozygous familial hypercholesterolemia patients worldwide: Interim results from the hofh international clinical collaborators (HICC) registry. <i>Atherosclerosis</i> , 2018 , 275, e80	3.1	2
133	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 280-290	18.1	148
132	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017 , 38, 2459-2472	9.5	1267
131	Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. <i>JAMA Cardiology</i> , 2017 , 2, 598-607	16.2	97
130	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1448-1457	4.9	32
129	Prevalence and pattern of dyslipidaemia in type 2 diabetes mellitus patients at a tertiary care hospital. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2017 , 22, 31-35	0.5	11

128	Analysis of mutations causing familial hypercholesterolaemia in black South African patients of different ancest. <i>South African Medical Journal</i> , 2017 , 107, 145-148	1.5	4
127	Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1162-1170	15.1	28
126	The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1843-1850	3.9	17
125	Effect of Alirocumab on Lipoprotein(a) Over 1.5 Years (from the Phase 3 ODYSSEY Program). <i>American Journal of Cardiology</i> , 2017 , 119, 40-46	3	98
124	Treatment Gaps Found in the Management of Type 2 Diabetes at a Community Health Centre in Johannesburg, South Africa. <i>Journal of Diabetes Research</i> , 2017 , 2017, 9536025	3.9	7
123	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 473-483	3.9	125
122	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 850-61	18.1	215
121	Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. <i>Data in Brief</i> , 2016 , 7, 1458-62	1.2	2
120	Pituitary apoplexy masquerading as meningitis. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2016 , 21, 3-4	0.5	
119	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 403-10	18.1	110
118	Multi-ethnic differences in HbA _{1c} , blood pressure, and low-density-lipid cholesterol control among South Africans living with type 2 diabetes, after a 4-year follow-up. <i>International Journal of General Medicine</i> , 2016 , 9, 419-426	2.3	5
117	Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). <i>Journal of Atherosclerosis and Thrombosis</i> , 2016 , 23, 567-87	4	38
116	The Effects of Mipomersen on Inhibiting Hepatic VLDL Apolipoprotein B100 Synthesis and Propensity for Hepatic Steatosis. <i>Clinical Chemistry</i> , 2016 , 62, 1052-3	5.5	3
115	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016 , 22, 1-32	1.7	60
114	Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. <i>Atherosclerosis</i> , 2016 , 248, 238-44	3.1	35
113	Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 860-869	4.9	30
112	Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 101-8	3.9	21
111	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor β role. <i>Journal of Lipid Research</i> , 2016 , 57, 1086-96	6.3	138

110	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 1647-50 ^{9.4}	19
109	Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig). <i>Atherosclerosis</i> , 2016 , 252, e44	3.1 4
108	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , 2015 , 372, 1489-99	59.2 1347
107	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , 2015 , 372, 1500-9	59.2 1081
106	Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2015 , 9, 201-9	4.9 21
105	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015 , 36, 2425-37	9.5 430
104	Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. <i>Current Cardiology Reports</i> , 2015 , 17, 104	4.2 17
103	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015 , 243, 257-9	3.1 123
102	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 2269-80	9.4 48
101	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015 , 385, 331-40	40 493
100	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015 , 385, 341-50	40 497
99	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015 , 36, 1012-22	9.5 770
98	Anacetrapib in familial hypercholesterolaemia: pros and cons. <i>Lancet, The</i> , 2015 , 385, 2124-6	40 4
97	Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 689-99	9.4 133
96	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 849-54	3.9 35
95	The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2015 , 132, 2167-92	16.7 377
94	The achievement of glycaemic, blood pressure and LDL cholesterol targets in patients with type 2 diabetes attending a South African tertiary hospital outpatient clinic. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2015 , 20, 81-86	0.5 11
93	The half-yellow man. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2015 , 20, 140-141 ^{6.5}	

92	Glycaemic, blood pressure and cholesterol control in 25 629 diabetics. <i>Cardiovascular Journal of Africa</i> , 2015 , 26, 188-92	0.7	17
91	Targeting LDL: is lower better and is it safe?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014 , 28, 309-24	6.5	23
90	What matters most in pediatric familial hypercholesterolemia, genotype or phenotype?. <i>Journal of Lipid Research</i> , 2014 , 55, 793-5	6.3	2
89	Effects of Long-Term, Monthly Administration of the PCSK9 Inhibitor Evolocumab in Patients with Dysglycemia or Metabolic Syndrome. <i>Canadian Journal of Diabetes</i> , 2014 , 38, S18	2.1	2
88	Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. <i>Annual Review of Medicine</i> , 2014 , 65, 417-31	17.4	69
87	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014 , 171, 309-25	3.2	251
86	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 655-66	18.1	357
85	Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. <i>Circulation</i> , 2014 , 129, 234-43	16.7	180
84	Trial evaluating evolocumab, a pcsk9 antibody, in patients with homozygous fh (tesla): Results of the randomized, double-blind, placebo-controlled trial. <i>Atherosclerosis</i> , 2014 , 235, e12	3.1	10
83	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. <i>European Heart Journal</i> , 2014 , 35, 2249-59	9.5	106
82	Lower levels of high-density lipoprotein cholesterol in urban Africans presenting with communicable versus non-communicable forms of heart disease: the Heart of Soweto Hospital registry study. <i>BMJ Open</i> , 2014 , 4, e005069	3	2
81	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014 , 35, 2146-57	9.5	614
80	New therapies for reducing low-density lipoprotein cholesterol. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014 , 43, 1007-33	5.5	31
79	A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. <i>HIV Medicine</i> , 2014 , 15, 3-12	2.7	12
78	Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1278-1288	15.1	266
77	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 148-72	4.9	79
76	Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. <i>PLoS ONE</i> , 2014 , 9, e102830	3.7	70
75	Polygenic familial hypercholesterolaemia: does it matter?. <i>Lancet, The</i> , 2013 , 381, 1255-7	40	16

74	Lomitapide for homozygous familial hypercholesterolaemia. <i>Lancet, The</i> , 2013 , 381, 7-8	40	22
73	Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. <i>Circulation</i> , 2013 , 128, 2113-20	16.7	246
72	The implementation of guidelines in a South African population with type 2 diabetes. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2013 , 18, 154-158	0.5	8
71	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013 , 34, 3478-90a	9.5	1551
70	Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. <i>Journal of the American Heart Association</i> , 2013 , 2, e000028	6	92
69	The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. <i>HIV Medicine</i> , 2013 , 14, 217-25	2.7	7
68	South African Dyslipidaemia Guideline Consensus Statement. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2013 , 55, 9-18	0.6	1
67	The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. <i>Clinical Lipidology</i> , 2013 , 8, 243-256		2
66	Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). <i>Cardiovascular Journal of Africa</i> , 2013 , 24, 330-8	0.7	12
65	Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. <i>Atherosclerosis</i> , 2012 , 223, 262-8	3.1	233
64	South African Dyslipidaemia Guideline Consensus Statement:. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012 , 17, 155-165	0.5	4
63	Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. <i>Hemodialysis International</i> , 2012 , 16, 59-68	1.7	7
62	Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. <i>Circulation</i> , 2012 , 126, 2408-17	16.7	386
61	High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. <i>Metabolic Syndrome and Related Disorders</i> , 2012 , 10, 351-7	2.6	13
60	Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease. <i>Cardiovascular Journal of Africa</i> , 2012 , 23, 389-95	0.7	28
59	A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. <i>BMC Infectious Diseases</i> , 2011 , 11, 244	4	47
58	Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. <i>Circulation</i> , 2011 , 124, 2202-7	16.7	235
57	CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. <i>Cardiovascular Journal of Africa</i> , 2011 , 22, 234-40	0.7	14

56	Comparison between surrogate indices of insulin sensitivity and resistance, and the hyperinsulinaemic euglycaemic glucose clamp in urban South African blacks with and without coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2010 , 7, 151-7	3.3	6
55	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2010 , 375, 998-1006	4.0	684
54	Case Studies: Unusual pheochromocytomas in African families: the importance of genetic testing. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2010 , 15, 92-94	0.5	3
53	Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. <i>Journal of Pediatrics</i> , 2010 , 156, 231-6.e1-3	3.6	49
52	The prevalence and incidence of and risk factors for, micro-albuminuria among urban Africans with type 1 diabetes in South Africa: An inter-ethnic study. <i>International Journal of Diabetes Mellitus</i> , 2010 , 2, 148-153		6
51	Leptin, adiponectin, and high-sensitivity C-reactive protein in relation to the metabolic syndrome in urban South African blacks with and without coronary artery disease. <i>Metabolic Syndrome and Related Disorders</i> , 2009 , 7, 243-8	2.6	22
50	Pathogenesis and management of the dyslipidemia of the metabolic syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2009 , 7, 83-8	2.6	32
49	Hypercholesterolemia in children and young adults—current management. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2009 , 14, 9-12	0.5	3
48	Postprandial hyperglycemia in urban South African blacks with and without coronary artery disease. <i>Metabolic Syndrome and Related Disorders</i> , 2009 , 7, 23-9	2.6	1
47	Statin benefits in people with cardiovascular risk factors only. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2009 , 14, 146-146	0.5	
46	A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2008 , 197, 400-6	3.1	71
45	New-onset diabetes mellitus after renal transplantation. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2008 , 13, 98-104	0.5	
44	Hypercholesterolaemia in children and young adults—current management. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2008 , 50, 7-10	0.6	
43	Postprandial lipaemia, metabolic syndrome and LDL particle size in urbanised South African blacks with and without coronary artery disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008 , 101, 111-9	2.7	13
42	The role of increased gastrointestinal alcohol production in patients with the metabolic syndrome: Implications for the pathogenesis of non-alcoholic fatty liver disease. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2008 , 13, 48-56	0.5	1
41	The metabolic syndrome using the National Cholesterol Education Program and International Diabetes Federation definitions among urbanised black South Africans with established coronary artery disease. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2007 , 12, 6-12	0.5	4
40	Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype. <i>Clinica Chimica Acta</i> , 2007 , 378, 33-7	6.2	10
39	Dyslipidaemia in diabetes—an approach to therapeutic intervention. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2006 , 48, 42-47	0.6	

38	Basal endocrine status in African dietary iron overload. <i>Endocrine</i> , 2003 , 21, 241-4		1
37	Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2003 , 171, 273-9	3.1	37
36	Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. <i>Transplantation</i> , 2002 , 73, 587-90	1.8	12
35	Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews. <i>American Journal of Human Genetics</i> , 2001 , 68, 1172-88	11	40
34	Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolemia--which is more important?. <i>Clinica Chimica Acta</i> , 2001 , 314, 167-73	6.2	3
33	From lipodystrophy syndromes to diabetes mellitus. <i>Lancet, The</i> , 2001 , 357, 1379-81	40	35
32	Lipoprotein(a) in homozygous familial hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 522-8	9.4	99
31	Circulating endothelium-related adhesion molecules in black South African patients with GravesR disease. <i>Endocrine</i> , 2000 , 12, 21-3		2
30	Cell adhesion molecules - can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia?. <i>Clinica Chimica Acta</i> , 2000 , 293, 105-13	6.2	26
29	Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2000 , 150, 421-8	3.1	70
28	Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. <i>Journal of Internal Medicine</i> , 1999 , 246, 75-80	10.8	11
27	Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 1999 , 83, 1330-3	3	44
26	Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 1999 , 84, 1344-6, A7	3	25
25	Two novel and two known low-density lipoprotein receptor gene mutations in German patients with familial hypercholesterolemia. <i>Human Mutation</i> , 1998 , Suppl 1, S232-3	4.7	3
24	Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. <i>Clinical Genetics</i> , 1998 , 54, 74-8	4	5
23	Mutation analysis in familial hypercholesterolemia patients of different ancestries: identification of three novel LDLR gene mutations. <i>Molecular and Cellular Probes</i> , 1998 , 12, 149-52	3.3	7
22	Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. <i>Atherosclerosis</i> , 1997 , 129, 97-102	3.1	15
21	Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 1997 , 135, 249-56	3.1	82

20	Plasma fatty acid levels in South African interethnic male high school pupils at different ultimate risks of coronary heart disease. <i>Clinica Chimica Acta</i> , 1997 , 258, 31-46	6.2	3
19	A double mutant LDL receptor allele in a cypriot family with heterozygous familial hypercholesterolemia. <i>Human Genetics</i> , 1997 , 100, 101-3	6.3	15
18	Insulin receptor substrate-1 gene variants in lipoatrophic diabetes mellitus and non-insulin-dependent diabetes mellitus: a study of South African black and white subjects. <i>Human Genetics</i> , 1997 , 101, 118-9	6.3	10
17	Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy. <i>Osteoporosis International</i> , 1997 , 7, 376-89	5.3	14
16	Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis?. <i>Clinical Endocrinology</i> , 1997 , 46, 365-8	3.4	22
15	CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. <i>Clinical Genetics</i> , 1997 , 51, 394-8	4	18
14	Screening for diabetic retinopathy in South Africa with 60 degrees retinal colour photography. <i>Journal of Internal Medicine</i> , 1996 , 239, 43-7	10.8	17
13	Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia. <i>Clinical Drug Investigation</i> , 1995 , 10, 127-38	3.2	21
12	Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 1995 , 113, 289-92	3.1	9
11	Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia. <i>Atherosclerosis</i> , 1995 , 115, 9-15	3.1	25
10	Low density lipoproteins and atherosclerosis-quantity or quality?. <i>Redox Report</i> , 1995 , 1, 171-6	5.9	6
9	Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. <i>American Journal of Clinical Nutrition</i> , 1994 , 60, 579-85	7	63
8	Insulin resistance or insulin deficiency as precursor of non-insulin-dependent diabetes mellitus. <i>Lancet, The</i> , 1994 , 344, 1705	4.0	3
7	Lack of effect of high dose vitamin E on xanthoma regression in homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 1994 , 107, 213-9	3.1	10
6	The age of onset and sex distribution of insulin-dependent diabetes mellitus in Africans in South Africa. <i>Postgraduate Medical Journal</i> , 1993 , 69, 552-6	2	34
5	Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993 , 13, 1076-81		23
4	Relationship between plasma insulin and blood pressure in South African black women in Johannesburg. <i>Diabetes Care</i> , 1992 , 15, 556-8	14.6	3
3	Insulin-receptor activity in nondiabetic and diabetic urbanized South African black women. <i>Diabetes Care</i> , 1992 , 15, 277-81	14.6	5

2	Pathogenesis of non-insulin-dependent diabetes mellitus in the black population of southern Africa. <i>Lancet, The</i> , 1992 , 340, 460-2	40	52
1	The relationship between the development and progression of microalbuminuria and arterial blood pressure in type 1 (insulin-dependent) diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 1992 , 16, 221-7	74	14